Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | No references |
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Bacillus anthracis | Anthrax lethal factor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Cytochrome P450 family protein | 0.0015 | 0.0013 | 0.0013 |
Leishmania major | cytochrome p450-like protein | 0.0015 | 0.0013 | 0.5 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0015 | 0.0013 | 0.5 |
Echinococcus multilocularis | MAP kinase activated protein kinase 2 | 0.3037 | 1 | 1 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Loa Loa (eye worm) | camk/mapkapk/mapkapk protein kinase | 0.3037 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0015 | 0.0013 | 0.0013 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0015 | 0.0013 | 0.0013 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0833 | 0.2718 | 0.2718 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 0.2718 | 0.2718 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0011 | 0 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0015 | 0.0013 | 0.0013 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Schistosoma mansoni | serine/threonine protein kinase | 0.3037 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0.0013 | 0.5 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0.0013 | 0.5 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0011 | 0 | 0.5 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0015 | 0.0013 | 0.0013 |
Echinococcus granulosus | MAP kinase activated protein kinase 2 | 0.3037 | 1 | 1 |
Trypanosoma brucei | cytochrome P450, putative | 0.0015 | 0.0013 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 0.2718 | 0.2718 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Anthrax Lethal Toxin Internalization. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (ADMET) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] | ChEMBL. | No reference |
Potency (ADMET) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] | ChEMBL. | No reference |
Potency (binding) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.